Free Trial
Andres Y. Maldonado

Andres Y. Maldonado Analyst Performance

Biotechnology Equity Research Analyst at HC Wainwright

Andres Y. Maldonado is a stock analyst at HC Wainwright in the medical sector, covering 9 publicly traded companies. Over the past year, Andres Y. Maldonado has issued 10 stock ratings, including and buy recommendations. While full access to Andres Y. Maldonado's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andres Y. Maldonado's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 0 Years
Buy Recommendations
100.00% 10 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%10 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
9 companies

Andres Y. Maldonado, an analyst at HC Wainwright, currently covers 9 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
9 companies
100.0%

Andres Y. Maldonado of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
8 companies
88.9%
MED - DRUGS
1 company
11.1%

Andres Y. Maldonado's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
9/23/2025Lower Price Target$32.37$44.00Buy
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
9/17/2025Reiterated Rating$10.27$40.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/15/2025Reiterated Rating$33.34$75.00Buy
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
9/10/2025Reiterated Rating$2.57$8.00Buy
enGene Holdings Inc. stock logo
ENGN
enGene
9/8/2025Reiterated Rating$5.18$25.00Buy
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/5/2025Reiterated Rating$32.52$75.00Buy
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
8/26/2025Initiated Coverage$30.42$70.00Buy
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
8/21/2025Reiterated Rating$4.52$7.00Buy
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
8/13/2025Reiterated Rating$7.21$22.00Buy
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
8/8/2025Lower Price Target$13.36$20.00Buy